| Title: |
Axillary lymphadenopathy at the time of COVID-19 vaccination:ten recommendations from the European Society of Breast Imaging (EUSOBI) |
| Authors: |
Schiaffino,Simone; Pinker,Katja; Magni,Veronica; Cozzi,Andrea; Athanasiou,Alexandra; Baltzer,Pascal A T; Camps Herrero,Julia; Clauser,Paola; Fallenberg,Eva M; Forrai,Gábor; Fuchsjäger,Michael H; Helbich,Thomas H; Kilburn-Toppin,Fleur; Kuhl,Christiane K; Lesaru,Mihai; Mann,Ritse M; Panizza,Pietro; Pediconi,Federica; Pijnappel, Ruud M; Sella,Tamar; Thomassin-Naggara,Isabelle; Zackrisson,Sophia; Gilbert,Fiona J; Sardanelli,Francesco; MS Radiologie; Cancer |
| Publication Year: |
2021 |
| Subject Terms: |
COVID-19 vaccines; Lymphadenopathy; Magnetic resonance imaging; Mammography; Ultrasonography (breast); Radiology Nuclear Medicine and imaging; Journal Article |
| Description: |
Unilateral axillary lymphadenopathy is a frequent mild side effect of COVID-19 vaccination. European Society of Breast Imaging (EUSOBI) proposes ten recommendations to standardise its management and reduce unnecessary additional imaging and invasive procedures: (1) in patients with previous history of breast cancer, vaccination should be performed in the contralateral arm or in the thigh; (2) collect vaccination data for all patients referred to breast imaging services, including patients undergoing breast cancer staging and follow-up imaging examinations; (3) perform breast imaging examinations preferentially before vaccination or at least 12 weeks after the last vaccine dose; (4) in patients with newly diagnosed breast cancer, apply standard imaging protocols regardless of vaccination status; (5) in any case of symptomatic or imaging-detected axillary lymphadenopathy before vaccination or at least 12 weeks after, examine with appropriate imaging the contralateral axilla and both breasts to exclude malignancy; (6) in case of axillary lymphadenopathy contralateral to the vaccination side, perform standard work-up; (7) in patients without breast cancer history and no suspicious breast imaging findings, lymphadenopathy only ipsilateral to the vaccination side within 12 weeks after vaccination can be considered benign or probably-benign, depending on clinical context; (8) in patients without breast cancer history, post-vaccination lymphadenopathy coupled with suspicious breast finding requires standard work-up, including biopsy when appropriate; (9) in patients with breast cancer history, interpret and manage post-vaccination lymphadenopathy considering the timeframe from vaccination and overall nodal metastatic risk; (10) complex or unclear cases should be managed by the multidisciplinary team. |
| Document Type: |
article in journal/newspaper |
| File Description: |
text/plain |
| Language: |
English |
| ISSN: |
1869-4101 |
| Relation: |
https://dspace.library.uu.nl/handle/1874/444625 |
| Availability: |
https://dspace.library.uu.nl/handle/1874/444625 |
| Rights: |
info:eu-repo/semantics/OpenAccess |
| Accession Number: |
edsbas.57AB74A |
| Database: |
BASE |